Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Lymphoma, B-Cell 2Plasmablastic Lymphoma 1Ovarian Neoplasms 1Oligodendroglioma 1Melanoma 1Margins of Excision 1Lymphomatoid Granulomatosis 1Lymphoma, Primary Effusion 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Glioma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Astrocytoma 1

Interventions

fludarabine phosphate 7pembrolizumab 6Mycophenolic Acid 6Peripheral Blood Stem Cell Transplantation 5Nivolumab 5Cyclosporine 5Cyclophosphamide 5Whole-Body Irradiation 4Radiotherapy 3Busulfan 3Antilymphocyte Serum 3temsirolimus 2fludarabine 2atezolizumab 2alectinib 2Tacrolimus 2Sunitinib 2Specimen Handling 2Paclitaxel 2Methotrexate 2Magnetic Resonance Spectroscopy 2Drug Therapy 2Dasatinib 2Alemtuzumab 2varlilumab 1valspodar 1utomilumab 1ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × varlilumab × Lymphoid × Clear all
NCT01460134 2018-01-31

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Celldex Therapeutics

Phase 1 Completed
90 enrolled
DermatologicGenitourinaryGynecologicLymphoidOther hematologic neoplasmThoracic

Margins of Excision, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Ovarian Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡